Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00168779
Status:
COMPLETED
Last Update Posted:
2017-12-28
First Post:
2005-09-12
Brief Title:
Randomized Double-Blind Placebo-Controlled Forced-Titration Comparing Telmisartan vs Valsartan Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Forced-titration Phase IV Study Comparing Telmisartan 80 mg Hydrochlorothiazide 25 mg Versus Valsartan 160 mg Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension
Status:
COMPLETED
Status Verified Date:
2017-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to compare the effectiveness of telmisartan 80 mg hydrochlorothiazide 25 mg Micardis HCT to valsartan 160 mg hydrochlorothiazide 25 mg Diovan HCT and placebo in the treatment of Stage 1 and Stage 2 hypertension
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None